Navigation Links
MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences
Date:8/6/2014

SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

  • The Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 9:10 a.m. Eastern time from Le Parker Meridien in New York; and
  • The 34th Annual Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 9:30 a.m. Eastern time from the InterContinental in Boston.

Live webcasts of the presentations can be accessed at www.meipharma.com. Replays will be available approximately one hour after the presentations.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor currently in development for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical study of Pracinostat in combination with azacitidine in patients with advanced MDS demonstrated an overall response rate of 90% (9 of 10). Preliminary data from an ongoing Phase II study of Pracinostat plus azacitidine in elderly patients with newly diagnosed AML showed responses in six of the first nine patients enrolled in the study (67%), including three patients who achieved a
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... financial results after the market closes on Tuesday, August ... conference call the same day at 4:30 p.m. ET ... provide a corporate update. The live call ...
(Date:7/28/2015)...  Champions Oncology, Inc. (OTC: CSBR), engaged in the ... the development and use of oncology drugs, today announced ... 2015. Fourth Quarter and Recent Business Highlights: ... prior year period result , Procured a quarterly ... Joel Ackerman, Champions Oncology CEO, stated, "The end of ...
(Date:7/28/2015)... July 28, 2015  Cepheid (Nasdaq: CPHD ... and portable clinical molecular diagnostic system designed to ... market.  At just 9 inches tall, and weighing ... the same high quality PCR-based Xpert® cartridges as ... accurate clinical molecular diagnostic tests to be performed ...
Breaking Medicine Technology:Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4
... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...
... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...
Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5
(Date:7/28/2015)... , ... July 28, 2015 , ... Healthpointe ’s ... that returns skin to a smooth state, and reduces the appearance of fine lines ... and only FDA-approved injectable gel to instantly add volume to your cheek area to ...
(Date:7/28/2015)... ... July 28, 2015 , ... According to WFTV on ... the lead among heroin toxicity cases. According to recent statistic Orlando suffers at least ... known as a hub of heroin, and law enforcement officials are struggling to keep ...
(Date:7/28/2015)... ... July 28, 2015 , ... BiologicsMD, Inc. , ... for the treatment of bone disorders and conditions of hair loss, announced that ... Proteins of Collagen Binding-Domain and Parathyroid Hormone". The issued patent claims methods of ...
(Date:7/28/2015)... ... 2015 , ... Women fear developing Alzheimer's disease more than having a heart ... stroke are treatable, but there is little an individual can do to arrest the ... a clinical trial, reports the July 2015 Harvard Women's Health Watch . , ...
(Date:7/28/2015)... Angeles, CA (PRWEB) , ... July 28, 2015 ... ... Sports entitled "A Breakdown of Mets' David Wright's Spinal Stenosis Injury" discussed ... the field. Wright’s spinal stenosis is acquired lumbar stenosis, brought on by degenerative ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... was announced that the,U.S. Court of Federal Claims ... favor of a child who regressed into autism ... the mercury-based preservative,thimerosal., Case documents state that ... underlying condition that ultimately led to,regressive encephalopathy and ...
... the University of Minnesota and North Carolina State University ... friendship and companionship they also share the same ... the researchers say that because of the way the ... some humans and dogs. , Jaime Modiano, V.M.D., Ph.D., ...
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Blue Cross and Blue,Shield,s Member Health Index has ... of the Blue Cross and Blue Shield Association, ... Shield companies are,working to increase the efficiency and ... Department of Health Care Policy,evaluates submissions from participating ...
... the full line of dermatologist endorsed moisturizers, ... the,makers of a full line of dermatologist endorsed ... skin conditions, is launching its 2008,"Prepare to Unveil ... looking and beautiful skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, ...
Cached Medicine News:Health News:Population Health Impact Institute Announces New Board Members 2Health News:Government Concludes Vaccines Caused Autism 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: